Ultromics Raises $55 Million To Scale Its AI-Enhanced Cardiology Diagnostic Solution For Undiagnosed Heart Failure

Ultromics, an artificial intelligence (AI) heart failure diagnostics innovator, announced that it has raised $55 million in Series C financing to scale its solutions in the United States. The round was co-led by L&G, Allegis Capital and Lightrock with continued support from Oxford Science Enterprises, GV Management Company, Blue Venture Fund and Oxford University, according to the announcement. Major U.S. health systems, such as UChicago Medicine’s venture investment vehicle (UCM Ventures), and UPMC Enterprises also participated in the round.

Ultromics offers the first U.S. Food and Drug Administration (FDA)-cleared, Medicare-reimbursed AI technology . . .